Eduardo Bruera, MD, of The University of Texas MD Anderson Cancer Center, discusses exciting developments in the assessment and management of cachexia, as well as a number of emerging pharmacologic and nonpharmacologic interventions (Abstract 67).
Anthony L. Back, MD, of Seattle Cancer Care Alliance, summarizes a general session on best practices and novel tools for enhancing communication between patients and oncology providers (Abstracts 8,9, 39).
Judith Paice, PhD, RN, of Northwestern University, reviews the current principles on assessing and treating neuropathic pain in cancer.
Amelie Harle, MD, of the Christie NHS Foundation Trust, discusses a clinical trial––the first of its kind—designed to assess the efficacy of an antitussive in patients with lung cancer (Abstract 2).
Diane Portman, MD, of Moffitt Cancer Center, discusses clinical pathways that embed palliative care along the spectrum of care for a variety of cancer disease states.
Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the encouraging study findings on olanzapine for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).
